AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer
First PARP plus PD1/L1-inhibitor Combo Data
Executive Summary
Combining a PARP inhibitor with a checkpoint inhibitor could improve outcomes in ovarian cancer patients, hint the early data from AstraZeneca’s Phase III DUO-O study of Lynparza and Imfinzi. How much broader a market now beckons for the two drugs remains uncertain, however.